13 / 64
SURTIME: The SURgery and TIMe
Phase III Study30073 of Sunitinib and Nephrectomy
Sunitinib
R
50 mg/day
(Schedule 4/2)
Nephrectomy
Patients with
synchronous
metastatic
A
N
D
O
M
I
Nephrectomy
Sunitinib
50 mg/day
RCC and
primary
tumour
in situ
N=458
S
A
T
I
O
i
d i
i
f
i l
(Schedule 4/2)
NCT01099423
N
Pr mary en po nt
:
progress on‐ ree surv va
Secondary endpoint
:
OS, association with prognostic gene and protein expression profiles
EORTC-GU Group Study